We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

License Agreement to Promote Development of Therapeutic CDK Inhibitors

By LabMedica International staff writers
Posted on 29 Jun 2015
Print article
A license agreement has been signed that was designed to promote the development and commercialization of a series of highly-selective cyclin-dependent kinase 7 (CDK7) inhibitors for the treatment of cancer, inflammation, and viral infections.

Cyclin-dependent kinases (CDKs) play a pivotal role in cell cycle control and transcription regulation and have long been considered attractive therapeutic targets. However, selective inhibitors have been difficult to develop, as the CDK active sites are highly conserved. Due to their outstanding specificity for CDK7, CDK inhibitors developed at The Lead Discovery Center (Dortmund, Germany) are thought to be good prospects for overcoming this hurdle. These compounds have demonstrated excellent potency and selectivity in vitro and in vivo.

In order to begin the process of commercializing their CDK inhibitors, The Lead Discovery Center has entered into a license agreement with Qurient Company (Gyeonggi, South Korea).

Under the terms of the agreement The Lead Discovery Center will receive an upfront payment and milestone payments upon the achievement of specific development events. Qurient will fund the future development activities of the collaborative program. The partners plan to progress from the validated lead stage into the clinical development phase. Upon successful proof-of-concept in humans, they will jointly identify a suitable partner for follow-on licensing.

“It is an exciting moment for Qurient to have The Lead Discovery Center as an upstream partner, providing innovative drug discovery programs to our "lead-to-clinical POC" pipelines,” said Dr. Kiyean Nam, CEO of Qurient. “We will join forces to achieve exceptional science and operational excellence until the program reaches mutually beneficial end point.”

“The partnership with Qurient is an essential part of our strategy to create versatile opportunities for accelerating the transfer of our leads into biopharmaceutical development,” said Dr. Bert Klebl, CEO of the Lead Discovery Center. “Qurient combines first-class development expertise with an exceptional commitment to moving innovative projects forward. Together, we can advance our projects swiftly into the clinic and benefit from the dynamic financial environment for biotech companies in South Korea.”

The Lead Discovery Center was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel way to capitalize on the potential of basic research for the discovery of new therapies for diseases with high medical need. Qurient began operations in 2009 as a venture capital funded spin-off Biotechnology company of the Institute Pasteur Korea and is dedicated to bridging gaps between innovative sciences and clinical development for unmet medical needs.

Related Links:

The Lead Discovery Center
Qurient Company


New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Automated Cell Counter
QuadCount
New
LH ELISA
Luteinizing Hormone ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The FDA clearance for the QIAstat-Dx Respiratory Panel Mini test follows the recent approval of QIAstat-Dx Respiratory Panel Plus (Photo courtesy of QIAGEN)

Respiratory Panel to Help Clinicians Make Precise Treatment Decisions in Outpatient Settings

Respiratory tract infections are the primary reason for visits to emergency departments and subsequent hospitalizations. In the U.S., it is estimated that there are up to 41 million cases of influenza... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: The new technique allows properties of cancer cells and their surrounding tissue to be analyzed in detail at single-cell level (Photo courtesy of Universität Helsinki/Karolina Punovuori)

New Imaging Method Opens Door to Precision Diagnostics for Head and Neck Cancers

Head and neck cancers, while considered rare, represent a significant portion of cancer cases and have seen a notable increase over the past 30 years. These cancers encompass various malignant tumors that... Read more